11
Peter Gross, Hans Jornvall, Grazyna Formicka Zeppezauer, Michael Zeppezauer, Michel Thiry: Bis-Met histones. Symbiotec Genellschaft zur Erforschung auf dem Geibeit der Biotechnologie MBH, Entralta P C, Annette S Parent, Peter D Weinstein, October 17, 2017: US09790259

The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing s ...


12
Peter Gross, Hans Jornvall, Grazyna Formicka Zeppezauer, Michael Zeppezauer, Michel Thiry: Bis-met histones. Symbiotec Genellschaft zur Erforschung auf dem Geibeit der Biotechnologie MBH, Entralta P C, Annette S Parent, Peter D Weinstein, October 24, 2017: US09796767

The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing s ...


13

14
Zeppezauer Michael, Schonberger Arno, Cebecauer Ladislav: Peptides entrant dans la fabrication de preparations utilisees pour le diagnostic et le traitement du lupus erythemateux aigu dissemine, Peptides for the production of preparations for the diagnosis and therapy of systemic lupus. Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der, OGILVY RENAULT SENCRLSRL, January 5, 1999: CA2078373

Peptides are proposed with antigenic or immunogenic determinants, which result from autoantibodies in the body fluids of patients, who are suffering from systemic lupus erythematosus (SLE). In the case of the peptides it is preferably a question of the C terminus of H1 with the sequence section 187 ...


15
Zeppezauer Michael, Leinenbach Hans Peter: Combinaison de substances presentant une activite cytostatique ou cytotoxique et utilisables dans le cadre dinterventions therapeutiques, Cytostatic or cytotoxic combination of active substances for use in therapeutic procedures. Zeppezauer Michael, Leinenbach Hans Peter, Symbiotec Gesellschaft Zur Forschung Und Entwicklung Auf Dem Gebiet Der, OGILVY RENAULT SENCRLSRL, January 21, 1997: CA2033249

According to this invention the combination of activesubstances for use in therapeutic procedures consists ofat least one cytostatic compound, e.g. vincristine,methotrexate, cisplatin as the first agent and at leastone histone and/or one active histone fragment withcytostatic or cytotoxic activity a ...


16
Zeppezauer Michael, Class Reiner: Use of histones for therapeutic purposes. Symbiotec Ges Fur Forschu, geqiang qinkai zong, April 30, 2008: CN200680015721

The invention relates to the use of at least one human recombinant histone, especially at least one histone H1 subtype, and/or a therapeutic histone fraction as a basis for the treatment of thrombocytopenia.


17

18
CLASS REINER, ZEPPEZAUER MICHAEL: COMPOSITIONS ANTIMICROBIENNES COMPRENANT LHISTONE H1, TROUSSES, ET MODES DEMPLOI DESDITES COMPOSITIONS, ANTIMICROBIAL HISTONE H1 COMPOSITIONS, KITS, AND METHODS OF USE THEREOF. SYMBIOTEC, PHILADELPHIA HEALTH AND EDUCATION CORPORATION, SYMBIOTEC, PHILADELPHIA HEALTH AND EDUCATION CORPORATION, MACRAE & CO, April 16, 2013: CA2379087

The invention includes antibiotic pharmaceutical compositions comprising eukaryotic histone H1 protein and methods of using eukaryotic histone H1 protein to kill or to inhibit the growth of microorganisms, including, but not limited to, human pathogenic bacteria. The invention further includes a euk ...


19

20
Zeppezauer Michael, Schoenberger Arno, Cebecauer Ladislav: Peptides for the production of preparations for the diagnosis and therapy of autoimmun diseases. Symbiotec Ges Zur Erforschung, September 1, 2004: EP1451220-A2

Peptides are proposed with antigenic or immunogenic determinants, which result from autoantibodies in the body fluids of patients, who are suffering from autoimmun diseases, in particular diseases of the rheumatic group as systemic lupus erythematosus (SLE), rheumatoid arthritis or systemic sclerosi ...